Elizabeth Harford-Wright

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11987371/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paracaspase MALT1 regulates glioma cell survival by controlling endoâ€lysosome homeostasis. EMBO Journal, 2020, 39, e102030.	3.5	33
2	Apelin, the Devil Inside Brain Tumors. Journal of Experimental Neuroscience, 2018, 12, 117906951875968.	2.3	9
3	Neutralizing gp130 interferes with endothelial-mediated effects on glioblastoma stem-like cells. Cell Death and Differentiation, 2017, 24, 384-384.	5.0	5
4	Pharmacological targeting of apelin impairs glioblastoma growth. Brain, 2017, 140, 2939-2954.	3.7	70
5	β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability. Oncotarget, 2016, 7, 66865-66879.	0.8	20
6	Desert Hedgehog/Patch2 Axis Contributes to Vascular Permeability and Angiogenesis in Glioblastoma. Frontiers in Pharmacology, 2015, 6, 281.	1.6	15
7	Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors. PLoS ONE, 2014, 9, e97002.	1.1	21
8	Differential Effects of 670 and 830 nm Red near Infrared Irradiation Therapy: A Comparative Study of Optic Nerve Injury, Retinal Degeneration, Traumatic Brain and Spinal Cord Injury. PLoS ONE, 2014, 9, e104565.	1.1	39
9	Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion. Clinical and Experimental Metastasis, 2013, 30, 1-12.	1.7	26
10	Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. Cancer Cell International, 2013, 13, 5.	1.8	13
11	NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anti-Cancer Drugs, 2013, 24, 344-354.	0.7	14
12	The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours. Recent Patents on CNS Drug Discovery, 2013, 8, 13-23.	0.9	7
13	Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. Journal of Neuroimmunology, 2012, 250, 59-65.	1.1	8
14	Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface. Recent Patents on CNS Drug Discovery, 2011, 6, 31-40.	0.9	8
15	Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neuroscience Letters, 2010, 481, 26-29.	1.0	42